Both POU6F1 and POU6F2 have been reported to suppress tumor proliferation (Yoshioka et al., 2009), and POU6F2 mutations have been implicated in the progression of Wilms tumor, hypogonadism, and pubertal failure in human patients (Cho et al., 2023). Here, POU6F1 is linked to hypogonadism.